On Monday, Adc Therapeutics SA (NYSE: ADCT) was -3.96% drop from the session before settling in for the closing price of $2.02. A 52-week range for ADCT has been $1.45 – $6.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 88.01% over the last five years. When this article was written, the company’s average yearly earnings per share was at 41.93%. With a float of $77.58 million, this company’s outstanding shares have now reached $96.69 million.
The firm has a total of 162 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.36%, operating margin of -196.67%, and the pretax margin is -235.56%.
Adc Therapeutics SA (ADCT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adc Therapeutics SA stocks. The insider ownership of Adc Therapeutics SA is 19.76%, while institutional ownership is 69.03%. The most recent insider transaction that took place on Dec 11 ’24, was worth 304,500. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $3.04, taking the stock ownership to the 15,666,731 shares. Before that another transaction happened on Dec 11 ’24, when Company’s 10% Owner bought 100,000 for $3.04, making the entire transaction worth $304,500. This insider now owns 13,145,712 shares in total.
Adc Therapeutics SA (ADCT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.93% per share during the next fiscal year.
Adc Therapeutics SA (NYSE: ADCT) Trading Performance Indicators
You can see what Adc Therapeutics SA (ADCT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.40, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.52 in one year’s time.
Technical Analysis of Adc Therapeutics SA (ADCT)
Analysing the last 5-days average volume posted by the [Adc Therapeutics SA, ADCT], we can find that recorded value of 0.79 million was lower than the volume posted last year of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 31.69%. Additionally, its Average True Range was 0.25.
During the past 100 days, Adc Therapeutics SA’s (ADCT) raw stochastic average was set at 8.28%, which indicates a significant decrease from 30.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.63% in the past 14 days, which was lower than the 131.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.42, while its 200-day Moving Average is $3.26. Now, the first resistance to watch is $2.07. This is followed by the second major resistance level at $2.21. The third major resistance level sits at $2.27. If the price goes on to break the first support level at $1.87, it is likely to go to the next support level at $1.81. Now, if the price goes above the second support level, the third support stands at $1.67.
Adc Therapeutics SA (NYSE: ADCT) Key Stats
There are 96,690K outstanding shares of the company, which has a market capitalization of 187.58 million. As of now, sales total 69,560 K while income totals -240,050 K. Its latest quarter income was 18,460 K while its last quarter net income were -43,970 K.
